Joy Wu, MD, PhD from Stanford University, has been elected as the Endocrine Society's President for 2027-2028, beginning her term in June 2026.
In a recent election, members of the Endocrine Society chose Joy Wu, MD, PhD, from the Stanford University School of Medicine in California, to serve as its President for the term 2027-2028. Wu's term as president-elect will begin in June 2026, leading up to her official presidency starting in June 2027.
Wu holds the position of Gerald M. Reaven, MD Professor of Endocrinology and is the chief of the Division of Endocrinology as well as vice chair of basic science in the Department of Medicine at Stanford. A board-certified endocrinologist, Wu specializes in the treatment of osteoporosis and various bone and mineral diseases.
Her work particularly emphasizes improving skeletal health in patients at heightened risk for bone loss due to cancer therapies. Wu also leads a research program that merges basic and translational science, concentrating on skeletal development and the bone marrow hematopoietic niche.
Currently, her laboratory is engaged in research regarding stem cell therapies aimed at enhancing bone formation and preventing cancer metastases to bone. Wu is a dedicated member of the Endocrine Society, having served on its Board of Directors and participated in several committees and task forces. Notably, she was part of the Society’s Hypercalcemia of Malignancy Guideline Writing Committee and holds an active role in its Bone and Mineral Special Interest Group.
Wu will assume the duties of President-Elect after ENDO 2026, the Society's annual meeting scheduled for June 13-16, 2026, in Chicago, Illinois. For more details about Wu and her contributions, refer to the May 2024 cover story in Endocrine News titled "The Joy of Endocrinology."
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.